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Comment on “Functional Analysis




n their published article, Giles et al. (1) explored func-
tional consequences of rs17611 in the TRAF1-C5 region
and propose a mechanism for its contribution to rheu-
matoid arthritis (RA) pathology, as this SNP would associate
with RA. To substantiate the claim that the SNP associates with
RA, the authors referred to the following studies: Refs. 2 and 3.
However, the data presented by Kurreeman et al. do not
indicate a significant association (p 5 0.19) in 544 subjects
(Ref. 2, see Table I). In addition, haplotype block analyses of
this risk locus shows that block 2 is significantly associated
with RA, while block 3 (which includes rs17611) is not (Ref.
2, see Fig. 1). Similar data by Plenge et al. (3) across 3372
subjects support this lack of association. Recent genome-wide
association studies data across 55,000 European subjects (4)
provide accurate estimations of risk across hundreds of SNPs
in this locus. Again, no signal of association for rs17611 has
been demonstrated in the available published datasets origi-
nating from this study (Fig. 1), which also shows that rs17611
is in relatively low linkage disequilibrium (LD) with the lead
SNP rs10985070 (r2 5 0.4). Moreover, independent secondary
association signals were not observed in the TRAF1-C5 locus
in a study by Eyre et al. (5), excluding the possibility that
rs17611 could represent a second hit at this locus.
On the basis of the published genetic data, we believe
caution should be taken in implicating the effects of rs17611
in relation to the immunological mechanism underlying the
genetic risk of TRAF1-C5 to RA.
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the European population as part of the Okada et al. paper (4): 14,361 RA cases and 43,923 controls from 18 studies of Europeans descent. Pairwise LD
values (r2) were calculated from individuals of the 1000 Genomes Project (CEU) relative to the highest associating SNP rs10985070 using SNAP (6). N.D.,
LD for SNP is not determined.
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n their Comment, Messemaker et al. discuss genetic data
that show that block 2 within the TRAF1-C5 locus is
a risk for rheumatoid arthritis (RA), while block 3 is not
associated. We acknowledge these data, which illustrate that,
when taken in isolation, block 3 does not impact disease risk.
It is clear that the genetic data are robust (1); however, there is
no question that the rs17611 single nucleotide polymorphism
(SNP) in C5 results in an amino acid change in C5 that alters
its rate of cleavage by elastase: an enzyme present at high levels
in neutrophil-driven or neutrophil-associated diseases such as
RA. We believe that it would be important and interesting to
further analyze whether this functional polymorphism in block
3, which affects the proinflammatory capacity of C5, has any
impact on the risk haplotype in block 2. While genome-wide
association studies have identified a number of independent
secondary association signals, these are not exclusive (2); the
strong functional data that we demonstrate with the C5-V802I
variant suggest that potential interactions should be specifically
tested in future studies to confirm or exclude them.
In our article (3), we reference other papers where the specific
rs17611 SNP has been linked to different diseases. Chai et al. (4)
show an association (p , 0.007) of rs17611 (and its linked set)
with periodontal disease; Woehrl et al. (5) show an association
(p , 0.002) of rs17611 with outcome in pneumococcal menin-
gitis; Hoke et al. (6) show an association (p , 0.01) of rs17611
with adverse cardiovascular outcome; and Greisenegger et al. (7)
show an association (p , 0.005) of rs17611 with risk for is-
chemic stroke. Together, these linkages provided a strong ra-
tionale to explore the functional consequences of the rs17611
SNP on C5 activities, the major focus of our paper.
First, we show that the rs17611 SNP is associated with clear
differences in C5 turnover and elevated levels of the proin-
flammatory product C5a in healthy individuals and RA
patients; our finding warrants further investigation of the
impact of this polymorphism on risk associated with block 2.
We go on to define the mechanism by which the single amino
acid change provokes these differences. The genetic data do not
detract from the importance of our demonstration that the
polymorphism impacts C5 turnover and increases plasma
levels of the proinflammatory molecule C5a, and of our de-
scription of the atypical route by which this is achieved (3).
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